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Abstract 
Review on RNF11, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: SID1669 
HGNC (Hugo): RNF11 
Location: 1p32.3 
Local order: According to NCBI Map Viewer, RNF11 
gene is located between: C1orf185 (chromosome 1 
open reading frame 185), CFL1P2 (cofilin1 
pseudogene 2) (in telomeric position); LOC100422413, 
EPS15 (epidermal growth factor receptor pathway 
substrate 15) TTC39A (tetratricopeptide repeat domain 
39A) (in centromeric position); the RPS2P8 (ribosomal 
protein S2 pseudogene 8) sequence maps to the minus 




According to NCBI Map Viewer, RNF11 gene is 
located at 51701945 - 51739119 (37175 bp) in  
human chromosome 1p32.3, plus strand. Unigene 
cluster Hs.309641, Entrez Gene ID: 26994. The human 
RNF11 gene is located in a genomic region where 
frequent alterations, deletions and chromosomal 
translocations, have been observed in T-cell acute 
lymphoblastic leukemia (Raimondi, 1993; Seki et al., 
1999). 
Description 
In humans, RNF11, the gene coding for RNF11, is 
located on human chromosome 1p32.3. The coding 
sequence spans more than 37 kb of genomic DNA, in 
the telomere-to-centromere orientation. 
Transcription 
The coding region of RNF11 is subdivided in 3 exons 
and includes additional 0,5 and 2,2 kb of 5' and 3' UTR 
regions, respectively. The open reading frame includes 
465 bp and codes for a protein of 154 amino acids. A 
very rare transcript encoding a sequence lacking exon 2 
has been identified (Kitching et al., 2003). RNA is 
expressed at low levels in lung, liver, kidney, pancreas, 
colon, spleen, prostate, thymus, ovary, small intestine 
and peripheral blood lymphocytes; stronger expression 
is observed in testes, heart, brain and placenta, while 
the highest level of RNF11 mRNA is in the skeletal 
muscle (Kitching et al., 2003). 
 
Analysis of the RNF11 genomic context. Adapted from NCBI. 
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DNA diagram of RNF11 gene. RNF11, Gene ID: 26994, chr: 51701945-51739119. Three exons. 
 
 
Cartoon representation of domain organization of RNF11. The WW-binding motif (PPPY) and the RING domain are shown. The 
asterisks (*) represent the acylated residues, Gly2 and Cys4 respectively. 
 
 
In tumor cell lines the strongest expression of the 
RNF11 transcript was reported in LnCAP prostate and 
HTB126 breast tumor cells (Kitching et al., 2003). In 
human brain RNF11 mRNA is detectable at similar 
levels in frontal cortex, striatum, hippocampus, pons 
and medulla (Pranski et al., 2012b). A functional 
consensus Ets1 transcription factor binding site (EBS) 
is conserved in the human and mouse RNF11 promoter 
and data suggest a role of Ets1 factor in RNF11 
expression during embryonic bone formation (Gao et 
al., 2005). The presence of a miR-19 target site in 3' 
UTR of RNF11 mRNA has been reported. Moreover, it 
has been demonstrated that miR-19b levels are 
inversely related with endogenous RNF11 mRNA 
levels (Gantier et al., 2012; Kumps et al., 2013), clearly 
indicating an important role for RNF11 in the effect of 
miR-19b on NF-κB signaling. 
Pseudogene 
No human pseudogene for RNF11 has been identified. 
Protein 
Description 
The RNF11 gene encodes for a 154 amino acid 17444 
kDa protein (Uniprot Q9Y3C5) that is ubiquitously 
expressed in human tissues. RNF11 amino acid 
sequence is strongly evolutionarily conserved. It 
contains a WW domain binding PPPY motif and a 
carboxy-terminal RING-H2 domain (C3H2C3-type 
RING finger), a variant RING finger motif carrying 
two histidines in place of cysteines. It binds two zinc 
atoms. The PY motif and the RING-H2 domain 
mediate protein-protein interactions involved in 
ubiquitin-mediated pathways. RNF11 interacts with the 
WW domains of the E3 ubiquitin-ligases NEDD4, 
ITCH, SMURF2 and WWP1 and it's ubiquitinated by 
Itch, Smurf2, UBE2D1 and WWP1 (Connor and Seth, 
2004; Santonico et al., 2010; Scheper et al., 2009; 
Subramaniam et al., 2003). The mature protein is 
anchored to intracellular membranes of the early 
endosome and the endosome recycling compartments 
(Santonico et al., 2010). Membrane binding requires 
two acylation motifs driving the myristoylation of Gly2 
and the S-palmitoylation of Cys4. Membrane 
anchoring via acylation is necessary in order for 
RNF11 to be post-translationally modified by the 
addition of several ubiquitin moieties (Santonico et al., 
2010). Four serine (Ser) residues have been identified 
as murine RNF11 phosphorylation sites (Ser7, Ser14, 
Ser25, Ser54) with differences between different 
tissues (Phosphomouse database). RNF11 is also 
phosphorylated on Threonine 135 by PKB/AKT1, 
promoting degradation by the proteasome (Connor et 
al., 2005). 
Expression 
The expression of this gene has been shown to be 
induced by mutant RET proteins (MEN2A/MEN2B). 
The germline mutations in RET gene are known to be 
responsible for the development of multiple endocrine 
neoplasia (MEN). The expression of RNF11 was also 
induced in TGW human neuroblastoma cells in 
response to glial cell line-derived neurotrophic factor 
stimulation (Watanabe et al., 2002). RNF11 is 
overexpressed in invasive breast cancers, in 
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adenocarcinomas of the pancreas, colon cancer and in 
bladder tumors (Subramaniam et al., 2003). Intense 
RNF11 expression was observed in osteoblasts in the 
mandible, calvarial bones and in the periosteal layer of 
developing endochondral bones of mouse embrios, 
while was undetectable in cartilage tissue at any stage 
of development. The expression of both the RNF11 
mRNA and protein was higher in the immature 
osteoblast than in the mature osteoblast (Gao et al., 
2005). RNF11 is variably expressed in neurons and 
excluded from white matter (Anderson et al., 2007). 
Localisation 
RNF11 is primarly cytoplasmic (early endosome, 
recycling endosome). Nuclear localization has been 
detected following phosphorylation by PKB/AKT1 
(Connor et al., 2005). The intracellular localization is 
dependent on the interaction of RNF11 with the GGA 
protein family of clathrin adaptors, involving the 
recognition of an N-terminal di-leucine motif in 
RNF11 by the VHS domain of GGA1 (Santonico et al., 
2010). 
Function 
Belongs to the RING E3-ligase protein family. RNF11 
interacts with UbcH5 a, b and c, and with Smurf2. The 
interaction causes ubiquitination of both RNF11 and 
Smurf2. RNF11 bound to Smurf2 can prevent Smurf2-
mediated ubiquitination of the TGFbeta receptor (Azmi 
and Seth, 2005); accordingly, the overexpression of 
RNF11 in transfected tumor cells can restore TGFbeta 
responsiveness (Subramaniam et al., 2003) while 
RNF11 knock-down abrogates the TGFbeta signal 
(Colland et al., 2004). RNF11 directly enhances TGF-
beta signalling by binding Smad4, the common Smad 
for TGF-beta, activin and BMP signalling and 
increasing and/or stabilizing Smad4 steady-state levels 
(Azmi and Seth, 2009). RNF11 binds WWP1, 
interfering with its function, and it cooperates with 
Smurf2 to degrade the de-ubiquitinating enzyme 
AMSH thus up-regulating EGFR and TGF-beta 
signalling (Chen et al., 2008; Li and Seth, 2004). 
RNF11 is an essential component of the A20 ubiquitin-
editing complex, comprising also RIP1, ITCH and 
TAX1BP1, which ensures the transient nature of 
inflammatory signaling pathways (Jacque and Ley, 
2009; Shembade et al., 2009; Verstrepen et al., 2010). 
RNF11 promotes the association of A20 to RIP1 in a 
TNF-dependent manner, leading to the inactivation of 
key signaling molecules. A20 deubiquitinates 'Lys-63' 
polyubiquitin chains on RIP1 and catalyzes the 
formation of 'Lys-48'-polyubiquitin chains. This leads 
to RIP1 proteosomal degradation and consequently 
termination of the TNF- or LPS-mediated activation of 
NF-kappa-B (Jacque and Ley, 2009; Shembade et al., 
2009). RNF11 has been shown to be involved in the 
regulation of EGFR degradation in the lysosomal  
 
compartment, by interacting with SARA and Hrs, both  
reported to be regulators of endocytic trafficking, on 
early-, late- and recycling endosome compartments. 
Data demonstrate that RNF11 and SARA participate 
structurally and functionally in the ESCRT-dependent 




An A to G transition (c124-2A>G) mutating the intron 
1 acceptor splice site of the RNF11 gene has been 
identified in bovine RNF11 gene. The RNA product 
corresponds to a transcript skipping exon 2 and with a 
frameshift appending illegitimate residues. The protein 
product is severely truncated (41/154 amino acids) and 




RNF11 is overexpressed in invasive breast cancers, in 
adenocarcinomas of the pancreas, colon cancer and in 




A direct involvement of RNF11 in oncogenesis has not 
been clearly established. Nevertheless, it has been 
shown that RNF11 competes with Smad7 in the 
interaction with Smurf2. Smurf2/Smad7 complex 
ubiquitinates TβRI leading to degradation of the 
receptor and TGFβ resistance in cancer cells, thus the 
interaction of RNF11 with Smurf2 could be important 
to restore TGFβ signalling. Furthermore, RNF11 also 
directly interacts with Smad4 and enhances its trans-
activation potential (Azmi and Seth, 2005).  
On the other side, it has also been suggested that 
RNF11 could stimulate the positive effects of the 
TGFβ signalling on later tumor progression and 
metastasis (Subramaniam et al., 2003). Other evidences 
of a putative function of RNF11 in oncogenesis come 
from the observation that RNF11 interacts with several 
proteins, such as E3 ubiquitin ligases and 
deubiquitinating enzymes, that are involved in 
oncogenesis. Among them, AMSH (associated 
moleculate with the SH3 domain of STAM) interacts 
with RNF11 and has been shown to upregulate BMP/ 
TGFβ signalling pathway by binding to Smad6 and 
Smad7. The interaction with RNF11 promotes AMSH 
degradation, probably mediated by Smurf2/RNF11 
complex and therefore abrogates the positive effects of 
AMSH on TGFβ signalling, leading to cell 
proliferation and malignant progression. 
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The RNF11 human interactome. RNF11 is involved in direct/enzymatic or indirect interactions with several proteins. The RNF11 human 
interactome is drawn according to MINT database. RNF11 interactors are clustered according to common biological function. The table 
below shows the Uniprot code and protein name of each RNF11 binding partner in the interaction network and the PubMed 
identifier(PMID) describing the interaction. The interactome browser mentha has been used to obtain the graphical representation  
(mentha: a resource to browse integrated protein interaction networks. 
In press; http://mentha.uniroma2.it/browser/index.html?ids=Q9Y3C5&org=9606). 
 
Parkinson's disease (PD) 
Note 
The gene RNF11 is contained within PARK10 and 
produced a signal of altered expression in PD brains 
(Noureddine et al., 2005). Moreover, in Parkinson 
disease, RNF11 is sequestered in Lewy bodies and 
neuritis. RNF11 is expressed by vulnerable neurons of 
the substantia nigra and it is involved in the protein 
degradation pathway mediated by the ubiquitin-
proteasome system (UPS), which has been repeatedly 
suggested as relevant in the etiology of PD (Anderson 
et al., 2007). RNF11 has been shown to modulate NF-
κB signaling in neuroblastoma cells and in primary 
cortical neurons, indicating a critical role in the 
regulation of regulating the inflammatory signaling in 
the central nervous system. Accordingly, depletion of 
RNF11 increases production of the inflammatory 
cytokine MCP-1 following TNF-α; activation, resulting 
in aberrant regulation of inflammatory signaling 
(Pranski et al., 2012a). Moreover, RNF11 has been 
shown to be a negative regulator of NF-κB signaling in 
microglial cell lines and confers protection against 
LPS-induced cell cytotoxicity (Dalal et al., 2012). 
Finally, loss of RNF11-mediated inhibition of NF-κB 
signaling in dopaminergic cells is protective against 6-
OHDA toxicity and promotes neuronal survival 
(Pranski et al., 2013). The effects observed following 
the reduced expression of RNF11 or the expression of 
functionally compromised mutants suggest that RNF11 
may have a role in neurodegenerative disease 
pathogenesis and progression. 
Alzheimer disease 
Note 
RNF11 is sequestered in Lewy bodies in human brains 
with Alzheimer disease with Lewy pathology. 
Regulation of the inflammatory 
response 
Note 
The splice site variant caused by the A to G transition 
c124-2A>G has been shown to compromise growth 
and regulation of the inflammatory response in Belgian 
Blue Cattle (Sartelet et al., 2012). RNF11 has been 
shown to negatively regulate NF-κB signaling in 
human monocytic cell lines by interacting with the A20 
ubiquitin-editing complex. Accordingly, depletion of 
RNF11 causes aberrant regulation of inflammatory 
signaling (Shembade et al., 2009). Endogenous RNF11 
mRNA levels have been reported to be inversely 
related with miR-19b levels (Gantier et al., 2012; 
Kumps et al., 2013), clearly indicating an important 
role for RNF11 in the effect of miR-19b on NF-κB 
signaling. Finally, RNF11 has been shown to act as 
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negative regulator of the RIG-I/MDA5 pathway and 
virus-induced IFN-beta production  
(Charoenthongtrakul et al., 2013). 
References 
Raimondi SC. Current status of cytogenetic research in 
childhood acute lymphoblastic leukemia. Blood. 1993 May 
1;81(9):2237-51 
Seki N, Hattori A, Hayashi A, Kozuma S, Sasaki M, Suzuki Y, 
Sugano S, Muramatsu MA, Saito T. Cloning and expression 
profile of mouse and human genes, Rnf11/RNF11, encoding a 
novel RING-H2 finger protein. Biochim Biophys Acta. 1999 
Dec 23;1489(2-3):421-7 
Watanabe T, Ichihara M, Hashimoto M et al.. Characterization 
of gene expression induced by RET with MEN2A or MEN2B 
mutation. Am J Pathol. 2002 Jul;161(1):249-56 
Kitching R, Wong MJ, Koehler D, Burger AM, Landberg G, 
Gish G, Seth A. The RING-H2 protein RNF11 is differentially 
expressed in breast tumours and interacts with HECT-type E3 
ligases. Biochim Biophys Acta. 2003 Oct 15;1639(2):104-12 
Subramaniam V, Li H, Wong M, Kitching R, Attisano L, Wrana 
J, Zubovits J, Burger AM, Seth A. The RING-H2 protein 
RNF11 is overexpressed in breast cancer and is a target of 
Smurf2 E3 ligase. Br J Cancer. 2003 Oct 20;89(8):1538-44 
Colland F, Jacq X, Trouplin V, Mougin C, Groizeleau C, 
Hamburger A, Meil A, Wojcik J, Legrain P, Gauthier JM. 
Functional proteomics mapping of a human signaling pathway. 
Genome Res. 2004 Jul;14(7):1324-32 
Connor MK, Seth A. A central role for the ring finger protein 
RNF11 in ubiquitin-mediated proteolysis via interactions with 
E2s and E3s. Oncogene. 2004 Mar 15;23(11):2089-95 
Li H, Seth A. An RNF11: Smurf2 complex mediates 
ubiquitination of the AMSH protein. Oncogene. 2004 Mar 
11;23(10):1801-8 
Azmi P, Seth A. RNF11 is a multifunctional modulator of 
growth factor receptor signalling and transcriptional regulation. 
Eur J Cancer. 2005 Nov;41(16):2549-60 
Connor MK, Azmi PB, Subramaniam V, Li H, Seth A. 
Molecular characterization of ring finger protein 11. Mol Cancer 
Res. 2005 Aug;3(8):453-61 
Gao Y, Ganss BW, Wang H, Kitching RE, Seth A. The RING 
finger protein RNF11 is expressed in bone cells during 
osteogenesis and is regulated by Ets1. Exp Cell Res. 2005 
Mar 10;304(1):127-35 
Noureddine MA, Li YJ, van der Walt JM et al.. Genomic 
convergence to identify candidate genes for Parkinson 
disease: SAGE analysis of the substantia nigra. Mov Disord. 
2005 Oct;20(10):1299-309 
Burger A, Amemiya Y, Kitching R, Seth AK. Novel RING E3 
ubiquitin ligases in breast cancer. Neoplasia. 2006 
Aug;8(8):689-95 
Anderson LR, Betarbet R, Gearing M, Gulcher J, Hicks AA, 
Stefánsson K, Lah JJ, Levey AI. PARK10 candidate RNF11 is 
expressed by vulnerable neurons and localizes to Lewy bodies 
in Parkinson disease brain. J Neuropathol Exp Neurol. 2007 
Oct;66(10):955-64 
Chen C, Zhou Z, Liu R, Li Y, Azmi PB, Seth AK. The WW 
domain containing E3 ubiquitin protein ligase 1 upregulates 
ErbB2 and EGFR through RING finger protein 11. Oncogene. 
2008 Nov 20;27(54):6845-55 
Azmi PB, Seth AK. The RING finger protein11 binds to Smad4 
and enhances Smad4-dependant TGF-beta signalling. 
Anticancer Res. 2009 Jun;29(6):2253-63 
Jacque E, Ley SC. RNF11, a new piece in the A20 puzzle. 
EMBO J. 2009 Mar 4;28(5):455-6 
Scheper J, Oliva B, Villà-Freixa J, Thomson TM. Analysis of 
electrostatic contributions to the selectivity of interactions 
between RING-finger domains and ubiquitin-conjugating 
enzymes. Proteins. 2009 Jan;74(1):92-103 
Shembade N, Parvatiyar K, Harhaj NS, Harhaj EW. The 
ubiquitin-editing enzyme A20 requires RNF11 to downregulate 
NF-kappaB signalling. EMBO J. 2009 Mar 4;28(5):513-22 
Santonico E, Belleudi F, Panni S, Torrisi MR, Cesareni G, 
Castagnoli L. Multiple modification and protein interaction 
signals drive the Ring finger protein 11 (RNF11) E3 ligase to 
the endosomal compartment. Oncogene. 2010 Oct 
14;29(41):5604-18 
Verstrepen L, Verhelst K, van Loo G, Carpentier I, Ley SC, 
Beyaert R. Expression, biological activities and mechanisms of 
action of A20 (TNFAIP3). Biochem Pharmacol. 2010 Dec 
15;80(12):2009-20 
Dalal NV, Pranski EL, Tansey MG, Lah JJ, Levey AI, Betarbet 
RS. RNF11 modulates microglia activation through NF-κB 
signalling cascade. Neurosci Lett. 2012 Oct 24;528(2):174-9 
Gantier MP, Stunden HJ, McCoy CE, Behlke MA et al.. A miR-
19 regulon that controls NF-κB signaling. Nucleic Acids Res. 
2012 Sep;40(16):8048-58 
Kostaras E, Sflomos G, Pedersen NM, Stenmark H, Fotsis T, 
Murphy C. SARA and RNF11 interact with each other and 
ESCRT-0 core proteins and regulate degradative EGFR 
trafficking. Oncogene. 2013 Oct 31;32(44):5220-32 
Pranski EL, Dalal NV, Herskowitz JH, Orr AL, Roesch LA, Fritz 
JJ, Heilman C, Lah JJ, Levey AI, Betarbet RS. Neuronal RING 
finger protein 11 (RNF11) regulates canonical NF-κB signaling. 
J Neuroinflammation. 2012a Apr 16;9:67 
Pranski EL, Van Sanford CD, Dalal NV, Orr AL, Karmali D, 
Cooper DS, Costa N, Heilman CJ, Gearing M, Lah JJ, Levey 
AI, Betarbet RS. Comparative distribution of protein 
components of the A20 ubiquitin-editing complex in normal 
human brain. Neurosci Lett. 2012b Jun 27;520(1):104-9 
Sartelet A, Druet T, Michaux C, Fasquelle C, Géron S, Tamma 
N, Zhang Z, Coppieters W, Georges M, Charlier C. A splice 
site variant in the bovine RNF11 gene compromises growth 
and regulation of the inflammatory response. PLoS Genet. 
2012;8(3):e1002581 
Charoenthongtrakul S, Gao L, Parvatiyar K, Lee D, Harhaj EW. 
RING finger protein 11 targets TBK1/IKKi kinases to inhibit 
antiviral signaling. PLoS One. 2013;8(1):e53717 
Kumps C, Fieuw A, Mestdagh P, Menten B et al.. Focal DNA 
copy number changes in neuroblastoma target MYCN 
regulated genes. PLoS One. 2013;8(1):e52321 
Pranski EL, Dalal NV, Sanford CV, Herskowitz JH, Gearing M, 
Lazo C, Miller GW, Lah JJ, Levey AI, Betarbet RS. RING finger 
protein 11 (RNF11) modulates susceptibility to 6-OHDA-
induced nigral degeneration and behavioral deficits through 
NF-κB signaling in dopaminergic cells. Neurobiol Dis. 2013 
Jun;54:264-79 
This article should be referenced as such: 
Santonico E, Mattioni A, Calderone A. RNF11 (ring finger 
protein 11). Atlas Genet Cytogenet Oncol Haematol. 2014; 
18(2):112-116. 
